BMS/Pfizer's Eliquis better than Lovenox, but comparison with Pradaxa and Xarelto not clear, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment body for England and Wales, has fast tracked Bristol-Myers Squibb's oral direct Factor Xa inhibitor, Eliquis (apixaban), through its appraisal process and has published final draft guidance recommending it for preventing blood clots after hip and knee surgery. The institute says it is both cheaper and more clinically effective than Sanofi's Lovenox, (enoxaparin). However, the jury is still out on how it compares to Boehringer Ingelheim's Pradaxa (dabigatran) and Bayer's Xarelto (rivaroxaban), partly because of the way in which the comparison was conducted.
You may also be interested in...
Canada Counters Drug Shortages With Export Bans
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
The COVID-19 Economic Crisis – Fallout And Opportunities
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Need a specific report? 1000+ reports available
Buy Reports